Seizures - Pipeline Review, H1 2016

  • ID: 3635561
  • Report
  • 201 pages
  • Global Markets Direct
1 of 5

FEATURED COMPANIES

  • Advicenne Pharma
  • GW Pharmaceuticals Plc
  • Novartis AG
  • Pfizer Inc.
  • RODES Inc.
  • Turing Pharmaceuticals AG
  • MORE
Seizures - Pipeline Review, H1 2016

Summary

The report ‘Seizures - Pipeline Review, H1 2016’, provides an overview of the Seizures pipeline landscape.

The report provides comprehensive information on the therapeutics under development for Seizures, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Seizures and features dormant and discontinued projects.

The report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data.

Scope

- The report provides a snapshot of the global therapeutic landscape of Seizures
- The report reviews pipeline therapeutics for Seizures by companies and universities/research institutes based on information derived from company and industry-specific sources
- The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages
- The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities
- The report reviews key players involved Seizures therapeutics and enlists all their major and minor projects
- The report assesses Seizures therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type
- The report summarizes all the dormant and discontinued pipeline projects
- The report reviews latest news related to pipeline therapeutics for Seizures

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
- Identify and understand important and diverse types of therapeutics under development for Seizures
- Identify potential new clients or partners in the target demographic
- Develop strategic initiatives by understanding the focus areas of leading companies
- Plan mergers and acquisitions effectively by identifying key players and it’s most promising pipeline therapeutics
- Devise corrective measures for pipeline projects by understanding Seizures pipeline depth and focus of Indication therapeutics
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
- Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
READ MORE
Note: Product cover images may vary from those shown
2 of 5

FEATURED COMPANIES

  • Advicenne Pharma
  • GW Pharmaceuticals Plc
  • Novartis AG
  • Pfizer Inc.
  • RODES Inc.
  • Turing Pharmaceuticals AG
  • MORE
List of Tables

List of Figures

Introduction

Report Coverage

Seizures Overview

Therapeutics Development

Pipeline Products for Seizures - Overview

Pipeline Products for Seizures - Comparative Analysis

Seizures - Therapeutics under Development by Companies

Seizures - Therapeutics under Investigation by Universities/Institutes

Seizures - Pipeline Products Glance

Late Stage Products

Clinical Stage Products

Early Stage Products

Unknown Stage Products

Seizures - Products under Development by Companies

Seizures - Products under Investigation by Universities/Institutes

Seizures - Companies Involved in Therapeutics Development

Adamas Pharmaceuticals, Inc.

Advicenne Pharma

Alexza Pharmaceuticals, Inc.

Biscayne Pharmaceuticals, Inc.

Catalyst Pharmaceutical Partners, Inc.

Eisai Co., Ltd.

GW Pharmaceuticals Plc

INSYS Therapeutics, Inc.

Marinus Pharmaceuticals, Inc.

Novartis AG

OPKO Health, Inc.

Pfizer Inc.

PTC Therapeutics, Inc.

RODES Inc.

Sage Therapeutics, Inc.

SciFluor Life Sciences, LLC

SK Biopharmaceuticals Co., Ltd.

Turing Pharmaceuticals AG

UCB S.A.

Ultragenyx Pharmaceutical Inc.

Upsher-Smith Laboratories, Inc.

Xenon Pharmaceuticals Inc.

XERIS Pharmaceuticals, Inc.

Zogenix, Inc.

Seizures - Therapeutics Assessment

Assessment by Monotherapy Products

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Drug Profiles

ADS-4101 - Drug Profile

ADV-6208 - Drug Profile

ADV-6770 - Drug Profile

alprazolam - Drug Profile

AMPX-0079 - Drug Profile

ataluren - Drug Profile

BIS-001 - Drug Profile

brivaracetam - Drug Profile

Cannabidiol - Drug Profile

CCG-63802 - Drug Profile

CHEC-9 - Drug Profile

clobazam - Drug Profile

CPP-115 - Drug Profile

CUR-1916 - Drug Profile

diazepam - Drug Profile

diazepam - Drug Profile

Epidiolex - Drug Profile

everolimus - Drug Profile

fenfluramine hydrochloride - Drug Profile

fosphenytoin sodium - Drug Profile

ganaxolone - Drug Profile

lacosamide - Drug Profile

levetiracetam - Drug Profile

lorazepam - Drug Profile

magnesium valproate hydrate - Drug Profile

MB-003 - Drug Profile

midazolam hydrochloride - Drug Profile

Oligonucleotide for Dravet Syndrome - Drug Profile

perampanel - Drug Profile

pregabalin - Drug Profile

SAGE-217 - Drug Profile

SAGE-689 - Drug Profile

selurampanel - Drug Profile

sepranolone - Drug Profile

SF-0034 - Drug Profile

Small Molecule for Stroke and Epilepsy - Drug Profile

Small Molecule to Block Nav1.6 for Dravet Syndrome - Drug Profile

Small Molecule to Inhibit GABA Transaminase for Migraine and Status Epilepticus - Drug Profile

Small Molecules for Seizures - Drug Profile

Small Molecules to Activate TrkB Receptor for Central Nervous System, Metabolic Disorders and ENT Disorders - Drug Profile

TG-4155 - Drug Profile

TRP-001 - Drug Profile

TUR-004 - Drug Profile

TUR-005 - Drug Profile

UX-007 - Drug Profile

YKP-3089 - Drug Profile

Seizures - Recent Pipeline Updates

Seizures - Dormant Projects

Seizures - Discontinued Products

Seizures - Product Development Milestones

Featured News & Press Releases

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List of Tables

Number of Products under Development for Seizures, H1 2016

Number of Products under Development for Seizures - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Number of Products under Development by Companies, H1 2016 (Contd..1)

Number of Products under Investigation by Universities/Institutes, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Development, H1 2016

Comparative Analysis by Unknown Stage Development, H1 2016

Products under Development by Companies, H1 2016

Products under Development by Companies, H1 2016 (Contd..1)

Products under Development by Companies, H1 2016 (Contd..2)

Products under Development by Companies, H1 2016 (Contd..3)

Products under Investigation by Universities/Institutes, H1 2016

Seizures - Pipeline by Adamas Pharmaceuticals, Inc., H1 2016

Seizures - Pipeline by Advicenne Pharma, H1 2016

Seizures - Pipeline by Alexza Pharmaceuticals, Inc., H1 2016

Seizures - Pipeline by Biscayne Pharmaceuticals, Inc., H1 2016

Seizures - Pipeline by Catalyst Pharmaceutical Partners, Inc., H1 2016

Seizures - Pipeline by Eisai Co., Ltd., H1 2016

Seizures - Pipeline by GW Pharmaceuticals Plc, H1 2016

Seizures - Pipeline by INSYS Therapeutics, Inc., H1 2016

Seizures - Pipeline by Marinus Pharmaceuticals, Inc., H1 2016

Seizures - Pipeline by Novartis AG, H1 2016

Seizures - Pipeline by OPKO Health, Inc., H1 2016

Seizures - Pipeline by Pfizer Inc., H1 2016

Seizures - Pipeline by PTC Therapeutics, Inc., H1 2016

Seizures - Pipeline by RODES Inc., H1 2016

Seizures - Pipeline by Sage Therapeutics, Inc., H1 2016

Seizures - Pipeline by SciFluor Life Sciences, LLC, H1 2016

Seizures - Pipeline by SK Biopharmaceuticals Co., Ltd., H1 2016

Seizures - Pipeline by Turing Pharmaceuticals AG , H1 2016

Seizures - Pipeline by UCB S.A., H1 2016

Seizures - Pipeline by Ultragenyx Pharmaceutical Inc., H1 2016

Seizures - Pipeline by Upsher-Smith Laboratories, Inc., H1 2016

Seizures - Pipeline by Xenon Pharmaceuticals Inc., H1 2016

Seizures - Pipeline by XERIS Pharmaceuticals, Inc., H1 2016

Seizures - Pipeline by Zogenix, Inc., H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Stage and Target, H1 2016

Number of Products by Stage and Mechanism of Action, H1 2016

Number of Products by Stage and Route of Administration, H1 2016

Number of Products by Stage and Molecule Type, H1 2016

Seizures Therapeutics - Recent Pipeline Updates, H1 2016

Seizures - Dormant Projects, H1 2016

Seizures - Dormant Projects (Contd..1), H1 2016

Seizures - Dormant Projects (Contd..2), H1 2016

Seizures - Discontinued Products, H1 2016

List of Figures

Number of Products under Development for Seizures, H1 2016

Number of Products under Development for Seizures - Comparative Analysis, H1 2016

Number of Products under Development by Companies, H1 2016

Comparative Analysis by Late Stage Development, H1 2016

Comparative Analysis by Clinical Stage Development, H1 2016

Comparative Analysis by Early Stage Products, H1 2016

Assessment by Monotherapy Products, H1 2016

Number of Products by Top 10 Targets, H1 2016

Number of Products by Stage and Top 10 Targets, H1 2016

Number of Products by Top 10 Mechanism of Actions, H1 2016

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2016

Number of Products by Routes of Administration, H1 2016

Number of Products by Stage and Routes of Administration, H1 2016

Number of Products by Molecule Types, H1 2016

Number of Products by Stage and Molecule Types, H1 2016
Note: Product cover images may vary from those shown
3 of 5

Loading
LOADING...

4 of 5
Adamas Pharmaceuticals, Inc.
Advicenne Pharma
Alexza Pharmaceuticals, Inc.
Biscayne Pharmaceuticals, Inc.
Catalyst Pharmaceutical Partners, Inc.
Eisai Co., Ltd.
GW Pharmaceuticals Plc
INSYS Therapeutics, Inc.
Marinus Pharmaceuticals, Inc.
Novartis AG
OPKO Health, Inc.
Pfizer Inc.
PTC Therapeutics, Inc.
RODES Inc.
Sage Therapeutics, Inc.
SciFluor Life Sciences, LLC
SK Biopharmaceuticals Co., Ltd.
Turing Pharmaceuticals AG
UCB S.A.
Ultragenyx Pharmaceutical Inc.
Upsher-Smith Laboratories, Inc.
Xenon Pharmaceuticals Inc.
XERIS Pharmaceuticals, Inc.
Zogenix, Inc.
Note: Product cover images may vary from those shown
5 of 5
Note: Product cover images may vary from those shown
Adroll
adroll